Waseem Hijazi1, Willam Leslie2, Neil Filipchuk1, Ryan Choo1, Stephen Wilton1, Matthew James3, Piotr J Slomka4, Robert J H Miller5. 1. Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, Calgary, AB, T2N 2T9, Canada. 2. Department of Nuclear Medicine, University of Manitoba, Winnipeg, MB, Canada. 3. Department of Medicine, Department of Community Health Sciences, O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 4. Departments of Medicine (Division of Artificial Intelligence in Medicine), Imaging and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 5. Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, Calgary, AB, T2N 2T9, Canada. robert.miller@albertahealthservices.ca.
Abstract
BACKGROUND: Single-photon emission computed tomography (SPECT) myocardial perfusion is frequently used to predict risk of major adverse cardiovascular events (MACE). We performed an external validation of the CRAX2MACE score, developed to estimate 2-year risk of MACE in patients with suspected coronary artery disease (CAD). METHODS: Patients who underwent clinically indicated SPECT with available follow-up for MACE were included (N = 2,985). The prediction performance for MACE (revascularization, myocardial infarction, or death) within 2 years for CRAX2MACE was compared with stress and ischemic total perfusion deficit (TPD) using area under the receiver operating characteristic curve (AUC). Calibration was assessed with calibration plots, Brier score, and the Hosmer-Lemeshow test. RESULTS: MACE occurred within 2 years in 243 (8.1%) patients. The AUC for CRAX2MACE (0.710, 95% CI 0.677-0.743) was significantly higher compared to stress TPD (AUC 0.669, 95% CI 0.632-0.706, P = .010) and ischemic TPD (AUC 0.664, 95% CI 0.627-0.700, P < .001). The model had acceptable goodness-of-fit (P = .103) and was well-calibrated with Brier score of 0.071. CONCLUSION: CRAX2MACE had higher predictive performance for 2-year MACE than quantitative perfusion in an external population. The current model is simple to use and could be implemented to assist physicians when estimating patient risk.
BACKGROUND: Single-photon emission computed tomography (SPECT) myocardial perfusion is frequently used to predict risk of major adverse cardiovascular events (MACE). We performed an external validation of the CRAX2MACE score, developed to estimate 2-year risk of MACE in patients with suspected coronary artery disease (CAD). METHODS: Patients who underwent clinically indicated SPECT with available follow-up for MACE were included (N = 2,985). The prediction performance for MACE (revascularization, myocardial infarction, or death) within 2 years for CRAX2MACE was compared with stress and ischemic total perfusion deficit (TPD) using area under the receiver operating characteristic curve (AUC). Calibration was assessed with calibration plots, Brier score, and the Hosmer-Lemeshow test. RESULTS: MACE occurred within 2 years in 243 (8.1%) patients. The AUC for CRAX2MACE (0.710, 95% CI 0.677-0.743) was significantly higher compared to stress TPD (AUC 0.669, 95% CI 0.632-0.706, P = .010) and ischemic TPD (AUC 0.664, 95% CI 0.627-0.700, P < .001). The model had acceptable goodness-of-fit (P = .103) and was well-calibrated with Brier score of 0.071. CONCLUSION: CRAX2MACE had higher predictive performance for 2-year MACE than quantitative perfusion in an external population. The current model is simple to use and could be implemented to assist physicians when estimating patient risk.
Authors: Piotr J Slomka; Hidetaka Nishina; Daniel S Berman; Cigdem Akincioglu; Aiden Abidov; John D Friedman; Sean W Hayes; Guido Germano Journal: J Nucl Cardiol Date: 2005 Jan-Feb Impact factor: 5.952
Authors: Yuka Otaki; Julian Betancur; Tali Sharir; Lien-Hsin Hu; Heidi Gransar; Joanna X Liang; Peyman N Azadani; Andrew J Einstein; Mathews B Fish; Terrence D Ruddy; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Sharmila Dorbala; Marcelo Di Carli; Balaji K Tamarappoo; Guido Germano; Damini Dey; Daniel S Berman; Piotr J Slomka Journal: JACC Cardiovasc Imaging Date: 2019-06-12
Authors: Lien-Hsin Hu; Tali Sharir; Robert J H Miller; Andrew J Einstein; Mathews B Fish; Terrence D Ruddy; Sharmila Dorbala; Marcelo Di Carli; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Julian Betancur; Guido Germano; Joanna X Liang; Frederic Commandeur; Peyman N Azadani; Heidi Gransar; Yuka Otaki; Balaji K Tamarappoo; Damini Dey; Daniel S Berman; Piotr J Slomka Journal: J Nucl Cardiol Date: 2019-05-13 Impact factor: 5.952
Authors: Robert W Yeh; Stephen Sidney; Malini Chandra; Michael Sorel; Joseph V Selby; Alan S Go Journal: N Engl J Med Date: 2010-06-10 Impact factor: 91.245
Authors: Alan Rozanski; Heidi Gransar; Sean W Hayes; James Min; John D Friedman; Louise E J Thomson; Daniel S Berman Journal: J Am Coll Cardiol Date: 2013-03-12 Impact factor: 24.094
Authors: Lien-Hsin Hu; Robert J H Miller; Tali Sharir; Frederic Commandeur; Richard Rios; Andrew J Einstein; Mathews B Fish; Terrence D Ruddy; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Sharmila Dorbala; Marcelo Di Carli; Joanna X Liang; Evann Eisenberg; Damini Dey; Daniel S Berman; Piotr J Slomka Journal: Eur Heart J Cardiovasc Imaging Date: 2021-05-10 Impact factor: 6.875
Authors: Cvetan Trpkov; Alexei Savtchenko; Zhiying Liang; Patrick Feng; Danielle A Southern; Stephen B Wilton; Matthew T James; Erin Feil; Ilias Mylonas; Robert J H Miller Journal: Int J Cardiol Heart Vasc Date: 2021-06-19
Authors: Evann Eisenberg; Robert J H Miller; Lien-Hsin Hu; Richard Rios; Julian Betancur; Peyman Azadani; Donghee Han; Tali Sharir; Andrew J Einstein; Sabahat Bokhari; Mathews B Fish; Terrence D Ruddy; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Sharmila Dorbala; Marcelo Di Carli; Joanna X Liang; Yuka Otaki; Balaji K Tamarappoo; Damini Dey; Daniel S Berman; Piotr J Slomka Journal: J Nucl Cardiol Date: 2021-07-06 Impact factor: 3.872